Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer

Nature

Volumn 559, Issue 7715, 2018, Pages 637-641

  Wu, Di ^a,b   Hu, Di ^a,b   Chen, Hao ^a,c   Shi, Guoming ^a,b   Fetahu, Irfete S ^b   Wu, Feizhen ^a,b   Rabidou, Kimberlie ^b   Fang, Rui ^b   Tan, Li ^a   Xu, Shuyun ^b   Liu, Hang ^a   Argueta, Christian ^b   Zhang, Lei ^d   Mao, Fei ^a   Yan, Guoquan ^d   Chen, Jiajia ^d   Dong, Zhaoru ^a   Lv, Ruitu ^a   Xu, Yufei ^b   Wang, Mei ^b   Ye, Yong ^a   Zhang, Shike ^b   Duquette, Danielle ^b   Geng, Songmei ^b   Yin, Clark ^b   Lian, Christine Guo ^b   Murphy, George F ^b   Adler, Gail K ^b   Garg, Rajesh ^b   Lynch, Lydia ^b   Yang, Pengyuan ^d   Li, Yiming ^a   Lan, Fei ^a   Fan, Jia ^a   Shi, Yang ^a,c   Shi, Yujiang Geno ^a,b   more..

^a FUDAN UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 HYDROXYMETHYLOME; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ADENYLATE KINASE; DNA; GLUCOSE; METFORMIN; SERINE; SHORT HAIRPIN RNA; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN TET2; UNCLASSIFIED DRUG; 5 METHYLCYTOSINE; 5-HYDROXYMETHYLCYTOSINE; DNA BINDING PROTEIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHOSERINE; TET2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; LETTER; MALE; MALIGNANT NEOPLASM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REGULATORY MECHANISM; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DNA METHYLATION; DRUG SCREENING; ENZYME SPECIFICITY; ENZYME STABILITY; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASM; NUDE MOUSE; PHOSPHORYLATION;

5-METHYLCYTOSINE; ADENYLATE KINASE; ANIMALS; DIABETES MELLITUS; DNA; DNA METHYLATION; DNA-BINDING PROTEINS; ENZYME STABILITY; EPIGENESIS, GENETIC; GLUCOSE; GLYCATED HEMOGLOBIN A; HUMANS; HYPERGLYCEMIA; METFORMIN; MICE; MICE, NUDE; NEOPLASMS; PHOSPHORYLATION; PHOSPHOSERINE; PROTO-ONCOGENE PROTEINS; SUBSTRATE SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85050664500     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/s41586-018-0350-5     Document Type: Article

References (30)

1. Nathan, D. M. Long-term complications of diabetes mellitus. N. Engl. J. Med. 328, 1676–1685 (1993).
2. Gregg, E. W. et al. Changes in diabetes-related complications in the United States, 1990–2010. N. Engl. J. Med. 370, 1514–1523 (2014).
3. Giovannucci, E. et al. Diabetes and cancer: a consensus report. CA Cancer J. Clin. 60, 207–221 (2010).
4. Chowdhury, T. A. Diabetes and cancer. QJM 103, 905–915 (2010).
5. Brower, V. Illuminating the diabetes-cancer link. J. Natl Cancer Inst. 104, 1048–1050 (2012).
6. Baylin, S. B. & Jones, P. A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 11, 726–734 (2011).
7. Jones, P. A. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 13, 484–492 (2012).
8. Ko, M., An, J. & Rao, A. DNA methylation and hydroxymethylation in hematologic differentiation and transformation. Curr. Opin. Cell Biol. 37, 91–101 (2015).
9. Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930–935 (2009).
10. Zhang, H. et al. TET1 is a DNA-binding protein that modulates DNA methylation and gene transcription via hydroxylation of 5-methylcytosine. Cell Res. 20, 1390–1393 (2010).
11. He, Y. F. et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333, 1303–1307 (2011).
12. Carey, B. W., Finley, L. W., Cross, J. R., Allis, C. D. & Thompson, C. B. Intracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 518, 413–416 (2015).
13. Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17–30 (2011).
14. Ko, M. et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468, 839–843 (2010).
15. Lian, C. G. et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150, 1135–1146 (2012).
16. Williams, K. et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 473, 343–348 (2011).
17. Xu, Y. et al. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol. Cell 42, 451–464 (2011).
18. Hardie, D. G., Ross, F. A. & Hawley, S. A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13, 251–262 (2012).
19. Hardie, D. G., Carling, D. & Carlson, M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu. Rev. Biochem. 67, 821–855 (1998).
20. de Lange, P. et al. Fuel economy in food-deprived skeletal muscle: signaling pathways and regulatory mechanisms. FASEB J. 21, 3431–3441 (2007).
21. Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167–1174 (2001).
22. Cool, B. et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 3, 403–416 (2006).
23. Kim, N. et al. AMPKα2 translocates into the nucleus and interacts with hnRNP H: implications in metformin-mediated glucose uptake. Cell. Signal. 26, 1800–1806 (2014).
24. Wang, Y. & Zhang, Y. Regulation of TET protein stability by calpains. Cell Reports 6, 278–284 (2014).
25. Ma, S. et al. Site-specific phosphorylation protects glycogen synthase kinase-3β from calpain-mediated truncation of its N and C termini. J. Biol. Chem. 287, 22521–22532 (2012).
26. Losman, J. A. et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339, 1621–1625 (2013).
27. Pernicova, I. & Korbonits, M. Metformin—mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol. 10, 143–156 (2014).
28. Morales, D. R. & Morris, A. D. Metformin in cancer treatment and prevention. Annu. Rev. Med. 66, 17–29 (2015).
29. Sander, V. et al. Role of the N, N′-dimethylbiguanide metformin in the treatment of female prepuberal BALB/c mice hyperandrogenized with dehydroepiandrosterone. Reproduction 131, 591–602 (2006).
30. Green, A. S. et al. LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology. Cell Cycle 10, 2115–2120 (2011).